Insider Selling: Maze Therapeutics (NASDAQ:MAZE) Insider Sells $210,150.00 in Stock

Posted by Brenda Bartman on Jul 4th, 2026

Maze Therapeutics, Inc. (NASDAQ:MAZE – Get Free Report) insider Atul Dandekar sold 7,500 shares of the stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $28.02, for a total transaction of $210,150.00. Following the transaction, the insider directly owned 26,250 shares in the company, valued at approximately $735,525. This represents a 22.22% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Atul Dandekar also recently made the following trade(s):

On Wednesday, April 29th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The shares were sold at an average price of $25.37, for a total transaction of $190,275.00.

Maze Therapeutics Price Performance

Shares of NASDAQ MAZE opened at $31.26 on Friday. The stock has a market capitalization of $1.73 billion, a PE ratio of -12.36 and a beta of 2.14. The company has a quick ratio of 17.88, a current ratio of 17.88 and a debt-to-equity ratio of 0.11. The firm has a fifty day moving average of $26.02 and a 200-day moving average of $35.64. Maze Therapeutics, Inc. has a 52-week low of $10.98 and a 52-week high of $53.65.

Maze Therapeutics (NASDAQ:MAZE – Get Free Report) last issued its earnings results on Tuesday, May 12th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.02). The company had revenue of $20.00 million during the quarter. On average, analysts anticipate that Maze Therapeutics, Inc. will post -2.73 EPS for the current year.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. Truist Financial dropped their target price on shares of Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating for the company in a research report on Tuesday, April 14th. Wedbush boosted their price objective on shares of Maze Therapeutics from $43.00 to $58.00 and gave the stock an “outperform” rating in a research note on Monday, March 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th. Mizuho raised shares of Maze Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 11th. Finally, HC Wainwright lifted their target price on shares of Maze Therapeutics from $60.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, March 25th. Two analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $66.00.

View Our Latest Stock Analysis on MAZE

Hedge Funds Weigh In On Maze Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Washington University boosted its stake in shares of Maze Therapeutics by 33.3% in the fourth quarter. Washington University now owns 280,802 shares of the company’s stock valued at $11,634,000 after purchasing an additional 70,121 shares during the period. Mass General Brigham Inc purchased a new stake in Maze Therapeutics during the 4th quarter worth $9,943,000. ArrowMark Colorado Holdings LLC purchased a new stake in Maze Therapeutics during the 3rd quarter worth $14,135,000. Boothbay Fund Management LLC lifted its holdings in Maze Therapeutics by 365.9% in the 3rd quarter. Boothbay Fund Management LLC now owns 351,875 shares of the company’s stock worth $9,124,000 after buying an additional 276,345 shares in the last quarter. Finally, Eventide Asset Management LLC acquired a new position in Maze Therapeutics in the 4th quarter worth $13,425,000.

Maze Therapeutics Company Profile

(Get Free Report)

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.